
Opinion|Videos|October 29, 2024
Putting Amivantamab Plus Lazertinib Into Practice
Author(s)Joshua K. Sabari, MD, Sandip Patel, MD
Panelists discuss key takeaways from the analysis of long-term results, noting that these findings may influence their recommendations for first-line regimens in EGFR-mutant metastatic non–-small cell lung cancer. They highlight how they engage patients in discussions about treatment options, considering efficacy and safety, while addressing remaining unmet needs in this therapeutic area.
Advertisement
Episodes in this series

Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.

The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Advertisement
Advertisement
Trending on CancerNetwork
1
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
2
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies
3
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
4
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
5


